ES2536002T3 - Marcadores para células pre-cancerígenas y cancerígenas y el método para interferir con la proliferación celular en ellas - Google Patents
Marcadores para células pre-cancerígenas y cancerígenas y el método para interferir con la proliferación celular en ellas Download PDFInfo
- Publication number
- ES2536002T3 ES2536002T3 ES10171926.8T ES10171926T ES2536002T3 ES 2536002 T3 ES2536002 T3 ES 2536002T3 ES 10171926 T ES10171926 T ES 10171926T ES 2536002 T3 ES2536002 T3 ES 2536002T3
- Authority
- ES
- Spain
- Prior art keywords
- cancer
- markers
- interfere
- cell proliferation
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- 230000004663 cell proliferation Effects 0.000 title 1
- 108091092236 Chimeric RNA Proteins 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000004611 cancer cell death Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009396 hybridization Methods 0.000 abstract 1
- 108091064355 mitochondrial RNA Proteins 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Una molécula de ARN quimérico mitocondrial aislada que comprende ARN ribosómico mitocondrial 16S sentido covalentemente ligado en su extremo 5' al extremo 3' de un polinucleótido con una secuencia de repetición invertida, en la que la molécula de ARN quimérica comprende una secuencia de nucleótidos seleccionada del grupo que consiste en SEC ID Nº: 1, SEC ID Nº: 2 y SEC ID Nº: 3.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47210603P | 2003-05-21 | 2003-05-21 | |
US472106P | 2003-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2536002T3 true ES2536002T3 (es) | 2015-05-19 |
Family
ID=33551438
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES04752867T Expired - Lifetime ES2365511T3 (es) | 2003-05-21 | 2004-05-21 | Marcadores para células precancerosas y cancerosas y método para interferir con la proliferación celular. |
ES10171933.4T Expired - Lifetime ES2618210T3 (es) | 2003-05-21 | 2004-05-21 | Marcadores para células precancerosas y cancerosas y el método para interferir con la proliferación celular de estas |
ES10171926.8T Expired - Lifetime ES2536002T3 (es) | 2003-05-21 | 2004-05-21 | Marcadores para células pre-cancerígenas y cancerígenas y el método para interferir con la proliferación celular en ellas |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES04752867T Expired - Lifetime ES2365511T3 (es) | 2003-05-21 | 2004-05-21 | Marcadores para células precancerosas y cancerosas y método para interferir con la proliferación celular. |
ES10171933.4T Expired - Lifetime ES2618210T3 (es) | 2003-05-21 | 2004-05-21 | Marcadores para células precancerosas y cancerosas y el método para interferir con la proliferación celular de estas |
Country Status (13)
Country | Link |
---|---|
US (6) | US8318686B2 (es) |
EP (3) | EP2264170B1 (es) |
JP (3) | JP5201834B2 (es) |
AT (1) | ATE506437T1 (es) |
BR (1) | BRPI0410789B8 (es) |
CA (1) | CA2526639C (es) |
DE (1) | DE602004032329D1 (es) |
DK (3) | DK2264170T3 (es) |
ES (3) | ES2365511T3 (es) |
HU (1) | HUE032575T2 (es) |
MX (1) | MXPA05012620A (es) |
PL (3) | PL2270159T3 (es) |
WO (1) | WO2005001030A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2264170B1 (en) | 2003-05-21 | 2017-02-08 | Andes Biotechnologies S.A. | Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein |
CA2585587C (en) * | 2004-10-29 | 2016-02-16 | Maarten Tjerk Penning | Methods using mitochondrial nucleic acid for determining a health status of an individual |
CN102589945B (zh) * | 2012-02-16 | 2013-10-23 | 中国人民解放军第三军医大学第二附属医院 | 骨髓涂片存放盒 |
WO2014153206A2 (en) * | 2013-03-14 | 2014-09-25 | Andes Biotechnologies S.A. | Methods for detecting and treating multiple myeloma |
EP2970970B1 (en) * | 2013-03-14 | 2018-12-12 | Andes Biotechnologies Global, Inc. | Antisense oligonucleotides for treatment of cancer stem cells |
US10519502B2 (en) | 2013-10-31 | 2019-12-31 | The Children's Hospital Of Philadelphia | Mitochondrial disease genetic diagnostics |
WO2015150924A2 (en) * | 2014-03-14 | 2015-10-08 | Andes Biotechnologies S.A. | Pharmaceutical compositions comprising rna and use for treating cancer |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
US6537973B1 (en) * | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US6265389B1 (en) * | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
US6426412B1 (en) * | 1995-12-20 | 2002-07-30 | Subsidiary No. 3, Inc. | Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements |
US6316210B1 (en) * | 1995-12-20 | 2001-11-13 | Subsidiary No. 3, Inc. | Genetic suppressor elements against human immunodeficiency virus |
US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US6720413B1 (en) | 1997-03-04 | 2004-04-13 | Musc Foundation For Research Development | Methods and compositions for diagnosis and treatment of cancer |
AU7499198A (en) | 1997-05-21 | 1998-12-11 | Johns Hopkins University, The | Gene expression profiles in normal and cancer cells |
US6071743A (en) | 1997-06-02 | 2000-06-06 | Subsidiary No. 3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
US6537972B1 (en) * | 1997-06-02 | 2003-03-25 | Subsidiary No. 3., Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
US6764822B1 (en) * | 1997-09-19 | 2004-07-20 | Sequenom, Inc. | DNA typing by mass spectrometry with polymorphic DNA repeat markers |
JP3251219B2 (ja) | 1997-10-13 | 2002-01-28 | 雅嗣 田中 | ヒトミトコンドリアdnaを用いた遺伝子検出方法 |
US6417169B1 (en) * | 1998-04-23 | 2002-07-09 | Genesense Technologies Inc. | Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth |
US20030092063A1 (en) * | 1998-05-15 | 2003-05-15 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO1999065928A2 (en) | 1998-06-19 | 1999-12-23 | Genzyme Corporation | Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues |
US6280946B2 (en) | 1998-08-07 | 2001-08-28 | Boston Probes, Inc. | PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya |
DE69938837D1 (de) * | 1998-11-04 | 2008-07-10 | Serono Genetics Inst Sa | Genomische und vollständige cdna sequenzen von menschlichem adipozyten spezifischem apm1 und biallelische marker davon |
US6576759B2 (en) * | 1999-02-10 | 2003-06-10 | Pangene Corporation | Antisense inhibition of RAD51 |
CA2370884A1 (en) | 1999-04-20 | 2000-10-26 | Mitokor | Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease |
WO2001016323A2 (en) * | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
US6573050B1 (en) * | 1999-10-29 | 2003-06-03 | Sunnybrook & Women's College Health Sciences Centre | Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma |
WO2001076532A2 (en) | 2000-04-11 | 2001-10-18 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
US6673917B1 (en) * | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
WO2002038759A2 (en) * | 2000-11-10 | 2002-05-16 | Mitotech Ab | Method for inducing apoptiosis |
JP4472253B2 (ja) * | 2000-12-04 | 2010-06-02 | プリマゲン ベー.フェー. | 内部共生体細胞小器官の検査およびそれで識別可能な化合物 |
US6573051B2 (en) * | 2001-03-09 | 2003-06-03 | Molecular Staging, Inc. | Open circle probes with intramolecular stem structures |
US6544958B2 (en) * | 2001-03-26 | 2003-04-08 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Therapy of respiratory influenza virus infection using free and liposome-encapsulated ribonucleotides |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2003020220A2 (en) * | 2001-08-30 | 2003-03-13 | Emory University | Mitochondrial biology expression arrays |
EP2264170B1 (en) * | 2003-05-21 | 2017-02-08 | Andes Biotechnologies S.A. | Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein |
US7374927B2 (en) * | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
-
2004
- 2004-05-21 EP EP10171933.4A patent/EP2264170B1/en not_active Expired - Lifetime
- 2004-05-21 ES ES04752867T patent/ES2365511T3/es not_active Expired - Lifetime
- 2004-05-21 HU HUE10171933A patent/HUE032575T2/en unknown
- 2004-05-21 BR BRPI0410789A patent/BRPI0410789B8/pt not_active IP Right Cessation
- 2004-05-21 ES ES10171933.4T patent/ES2618210T3/es not_active Expired - Lifetime
- 2004-05-21 WO PCT/US2004/015929 patent/WO2005001030A2/en active Application Filing
- 2004-05-21 PL PL10171926T patent/PL2270159T3/pl unknown
- 2004-05-21 EP EP04752867A patent/EP1625142B1/en not_active Expired - Lifetime
- 2004-05-21 ES ES10171926.8T patent/ES2536002T3/es not_active Expired - Lifetime
- 2004-05-21 PL PL10171933T patent/PL2264170T3/pl unknown
- 2004-05-21 PL PL04752867T patent/PL1625142T3/pl unknown
- 2004-05-21 DK DK10171933.4T patent/DK2264170T3/en active
- 2004-05-21 EP EP20100171926 patent/EP2270159B1/en not_active Expired - Lifetime
- 2004-05-21 MX MXPA05012620A patent/MXPA05012620A/es active IP Right Grant
- 2004-05-21 DK DK04752867.4T patent/DK1625142T3/da active
- 2004-05-21 US US10/557,458 patent/US8318686B2/en active Active
- 2004-05-21 AT AT04752867T patent/ATE506437T1/de active
- 2004-05-21 JP JP2006533267A patent/JP5201834B2/ja not_active Expired - Lifetime
- 2004-05-21 DK DK10171926.8T patent/DK2270159T3/en active
- 2004-05-21 DE DE602004032329T patent/DE602004032329D1/de not_active Expired - Lifetime
- 2004-05-21 CA CA2526639A patent/CA2526639C/en not_active Expired - Lifetime
-
2012
- 2012-09-26 US US13/627,965 patent/US8895719B2/en not_active Expired - Lifetime
- 2012-12-10 JP JP2012269587A patent/JP5775057B2/ja not_active Expired - Fee Related
-
2014
- 2014-09-05 US US14/479,143 patent/US9359648B2/en not_active Expired - Lifetime
- 2014-12-03 JP JP2014244747A patent/JP2015096069A/ja active Pending
-
2016
- 2016-04-26 US US15/139,255 patent/US9903000B2/en not_active Expired - Lifetime
-
2018
- 2018-01-10 US US15/867,627 patent/US10876166B2/en not_active Expired - Lifetime
-
2020
- 2020-11-24 US US17/103,671 patent/US20210348236A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116876T1 (el) | Ολιγονουκλεοτιδικα αναλογα που ενσωματωνουν 5-αζα-κυτοσινη σε αυτα | |
CR9315A (es) | Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia | |
DK2092065T4 (da) | Antisense-forbindelser | |
HRP20070012A2 (en) | Immunostimulatory oligonucleotide multimers | |
CY1124197T1 (el) | Antinohmatika πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
ATE498693T1 (de) | Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatienten | |
CY1117499T1 (el) | 5'-τριφωσφορικο ολιγονουκλεοτιδιο με κολοβωμενο ακρο και χρησεις εξ΄αυτου | |
ES2536002T3 (es) | Marcadores para células pre-cancerígenas y cancerígenas y el método para interferir con la proliferación celular en ellas | |
ATE512146T1 (de) | Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen | |
GT200500308A (es) | Nonadepsipeptidos acilados ii | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
WO2008087558A3 (en) | Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use | |
IL163672A0 (en) | Microorganisms as carriers of nucleotide sequencescoding for cell antigens used for the treatment o f tumors | |
WO2009115927A3 (en) | Nucleotide analogues with quaternary carbon stereogenic centers and methods of use | |
DE602004022921D1 (de) | Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen | |
Cheng et al. | Isolation and characterization of 23 microsatellite loci in the Chinese sucker (Myxocyprinus asiaticus) | |
ATE428786T1 (de) | Antisense-oligonukleotid mit antikrebsaktivität | |
TH27550S1 (th) | ชุดฝึกทักษะการเขียน | |
WO2006051333A3 (en) | Leucine-rich repeat (lrr) motif containing proteins | |
TH94277A (th) | อนุพันธ์พิริมิดีนที่เชื่อมต่อกับออกซิเจน | |
TH81136S (th) | หลอดไฟฟ้า | |
TH61565S (th) | แหวน | |
TH67619S (th) | กรงสัตว์เลี้ยง | |
CY1114199T1 (el) | Αντιπληροφοριακη διαμορφωση της εκφρασης της απολιποπρωτεϊνης β | |
TH70114S (th) | ชุดฝึกทักษะการเขียน |